European CHMP recommends approval of pitolisant (Ozawade) for treatment of excessive daytime sleepiness with obstructive sleep apnoea

Approval of this inverse agonist of histamine receptor type 3 is to reduce excessive daytime sleepiness (EDS) in adults with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated with OSA primary therapy, such as continuous positive airway pressure. .

Source:

European Medicines Agency